Protocol Ledger

NCT03365791 · Phase II · COMPLETED

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Interventional Phase II clinical trial protocol NCT03365791 sponsored by Novartis in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-24 Enrollment: 76 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03365791
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)76 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03365791
Protocol FieldVerified Registry Value
NCT IdentifierNCT03365791
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment76 participants (ACTUAL)
Registered Start Date2018-01-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI